Table 1 Differences between enrolled patients with and without WO and dyskinesia
Items | WO | Dyskinesia | ||||
|---|---|---|---|---|---|---|
With (n = 724) | Without (n = 834) | P value | With (n = 160) | Without (n = 1398) | P value | |
Age, years | <.0001 | 0.0016 | ||||
Mean ± SD | 63.8 ± 9.6 | 66.5 ± 9.3 | 63.0 ± 9.5 | 65.5 ± 9.5 | ||
n (missing) | 710(14) | 815(19) | 156(4) | 1369(29) | ||
Gender, Female | 0.0422 | 0.1959 | ||||
n (%) | 347(47.9) | 356(42.8) | 80(50.0) | 623(44.6) | ||
n (missing) | 724(0) | 832(2) | 160(0) | 1396(2) | ||
Height, cm | 0.2230 | 0.2203 | ||||
Mean ± SD | 164.1 ± 7.8 | 164.6 ± 7.7 | 163.6 ± 8.3 | 164.4 ± 7.7 | ||
n (missing) | 717(7) | 826(8) | 157(3) | 1386(12) | ||
Weight, kg | 0.0090 | <.0001 | ||||
Mean ± SD | 60.9 ± 11.1 | 62.3 ± 10.7 | 58.46 ± 10.12 | 62.01 ± 10.91 | ||
n (missing) | 720(4) | 826(8) | 158(2) | 1388(10) | ||
Onset age, years | <.0001 | <.0001 | ||||
Mean ± SD | 57.3 ± 9.9 | 62.3 ± 9.5 | 54.9 ± 9.9 | 60.5 ± 9.9 | ||
n (missing) | 711(13) | 783(51) | 156(4) | 1338(60) | ||
Disease duration, years | <.0001 | <.0001 | ||||
Mean ± SD | 6.7 ± 4.4 | 4.2 ± 3.7 | 8.2 ± 5.5 | 5.1 ± 4.0 | ||
n (missing) | 713(11) | 796(38) | 155(5) | 1354(44) | ||
UPDRS-III* | <.0001 | 0.1678 | ||||
Mean ± SD | 19.0 ± 8.4 | 15.6 ± 6.7 | 18.8 ± 9.1 | 17.8 ± 7.9 | ||
n (missing) | 724(0) | 327(0) | 160(0) | 891(0) | ||
L-dopa duration, years | <.0001 | <.0001 | ||||
Mean ± SD | 5.1 ± 3.9 | 3.3 ± 3.5 | 5.9 ± 4.7 | 3.9 ± 3.7 | ||
n (missing) | 703(21) | 785(49) | 151(9) | 1337(61) | ||
L-dopa dosage | <.0001 | <.0001 | ||||
Mean ± SD | 478.5 ± 247.0 | 355.4 ± 191.5 | 581.7 ± 311.4 | 393.8 ± 207.7 | ||
n (missing) | 724(0) | 834(0) | 160(0) | 1398(0) | ||
≤400 mg/d n (%) | 359(37.2) | 607(62.8) | <.0001 | 52(5.4) | 914(94.6) | <.0001 |
400-600 mg/d n (%) | 234(56.5) | 180(43.5) | 54(13.0) | 360(87.0) | ||
>600 mg/d n (%) | 131(73.6) | 47(26.4) | 54(30.3) | 124(69.7) | ||
LED | <.0001 | <.0001 | ||||
Mean ± SD | 558.4 ± 281.7 | 414.4 ± 216.0 | 707.8 ± 336.9 | 455.4 ± 234.9 | ||
n (missing) | 724(0) | 834(0) | 160(0) | 1398(0) | ||
ADL* | <.0001 | <.0001 | ||||
Mean ± SD | 28.4 ± 12.9 | 21.0 ± 9.6 | 31.3 ± 13.6 | 25.1 ± 12.0 | ||
n (missing) | 721(3) | 326(1) | 160(0) | 887(4) | ||
Medications for PD, n (%) | ||||||
Levodopa-benserazide | 647(89.4) | 682(81.8) | <.0001 | 136(85.0) | 1193(85.3) | 0.9094 |
Levodopa-carbidopa | 285(39.4) | 253(30.3) | 0.0002 | 87(54.4) | 451(32.3) | <.0001 |
Pramipexole | 245(33.8) | 266(31.9) | 0.4147 | 58(36.3) | 453(32.4) | 0.3262 |
Piribedil | 196(27.1) | 168(20.1) | 0.0013 | 66(41.3) | 298(21.3) | <.0001 |
Entacapone | 152(21.0) | 109(13.1) | <.0001 | 43(26.9) | 218(15.6) | 0.0003 |
Selegiline | 17(2.4) | 32(3.8) | 0.0931 | 4(2.5) | 45(3.2) | 0.6216 |
Trihexyphenidyl | 101(13.9) | 114(13.7) | 0.8725 | 17(10.6) | 198(14.2) | 0.2190 |
Amantadine | 174(24.0) | 182(21.8) | 0.3000 | 46(28.8) | 310(22.2) | 0.0606 |